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A B S T R A C T
Purpose
Dysregulated microRNAs are implicated in the pathogenesis and aggressiveness of acute myeloid
leukemia (AML). We describe the effect of the hematopoietic stem-cell self-renewal regulatingmiR-
193b on progression and prognosis of AML.
Methods
We proﬁled miR-193b-5p/3p expression in cytogenetically and clinically characterized de novo
pediatric AML (n = 161) via quantitative real-time polymerase chain reaction and validated our
ﬁndings in an independent cohort of 187 adult patients. We investigated the tumor suppressive
function of miR-193b in human AML blasts, patient-derived xenografts, and miR-193b knockout
mice in vitro and in vivo.
Results
miR-193b exerted important, endogenous, tumor-suppressive functions on the hematopoietic
system. miR-193b-3p was downregulated in several cytogenetically deﬁned subgroups of pediatric
and adult AML, and low expression served as an independent indicator for poor prognosis in pe-
diatric AML (risk ratio6 standard error,20.566 0.23; P = .016). miR-193b-3p expression improved
the prognostic value of the European LeukemiaNet risk-group stratiﬁcation or a 17-gene leukemic
stemness score. In knockout mice, loss of miR-193b cooperated with Hoxa9/Meis1 during leu-
kemogenesis, whereas restoring miR-193b expression impaired leukemic engraftment. Similarly,
expression of miR-193b in AML blasts from patients diminished leukemic growth in vitro and in
mouse xenografts. Mechanistically, miR-193b induced apoptosis and a G1/S-phase block in various
human AML subgroups by targeting multiple factors of the KIT-RAS-RAF-MEK-ERK (MAPK) sig-
naling cascade and the downstream cell cycle regulator CCND1.
Conclusion
The tumor-suppressive function is independent of patient age or genetics; therefore, restoring
miR-193b would assure high antileukemic efﬁcacy by blocking the entire MAPK signaling cascade
while preventing the emergence of resistance mechanisms.
J Clin Oncol 36:1007-1016. © 2018 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
MicroRNAs (miRNAs) are short, noncoding RNAs
that drew large interest as posttranscriptional
master regulators of gene expression, often tar-
geting hundreds of different mRNAs with both
temporal and spatial speciﬁcity.1,2 Their ability to
orchestrate individual pathways at various levels or
many pathways simultaneously gives them a central
role in developmental, physiologic, and pathologic
processes.3,4 Accordingly, many of the miRNAs
identiﬁed to date are associated with cancer and
can act at different stages of tumor development.5-9
Therefore, modulating miRNAs may be a prom-
ising strategy to advance targeted cancer therapies.
First, they represent a new class of druggable
molecules, distinct from classic drug targets in
cancer (ie, proteins). Second, they are key regu-
lators that control multiple important path-
ways simultaneously, reducing the possibility
of single-target resistance mechanisms.10 Third,
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miRNA-modulating therapeutics have been proven feasible with
minimal adverse events in preclinical and clinical trials.11-14
In many cancers, including acute myeloid leukemia (AML),
activating mutations in genes encoding growth factor receptors,
such as FLT3 or KIT, or their downstream effectors have been
identiﬁed.15,16 The KIT-RAS-RAF-MEK-ERK (MAPK) pathway
connects signals from cell-surface receptors to transcription fac-
tors, regulating gene expression and proteins involved in the cell
cycle and apoptosis.17-19 In AML cells, abnormalities in KIT (19%
to 40% in pediatric and adult AMLs)15,16 or the downstream small
GTP-binding protein KRAS (10% to 20% in pediatric and adult
AMLs) are common.20 Despite the development of efﬁcient RAF
and tyrosine-kinase inhibitors, however,21,22 current clinical trials
have failed to prove a survival beneﬁt for the treated patients,
suggesting that leukemic cells quickly adapt and use alternative
signaling routes.10 Therefore, novel strategies that target theMAPK
signaling cascade at multiple levels are warranted, preferably with
a single drug, to achieve more efﬁcient eradication of the leukemic
clone.
In previous studies, we demonstrated that miR-193b is reg-
ulated by STAT5 signaling and controls hematopoietic stem and
progenitor cell self-renewal and expansion by modulating the
expression of KIT.23 Given the central role of miR-193b as
a negative regulator of hematopoietic stem and progenitor cell
physiology, we investigated miR-193b in leukemogenesis and as
a prognostic factor in pediatric and adult AML.
PATIENTS AND METHODS
For detailed methods, see the Data Supplement.
Patient Samples
Adult AML samples for in vitro assays were collected from patients
enrolled in the German-Austrian AML Study Group (AMLSG) treatment
protocols for younger adults (AMLSG-HD98A [ClinicalTrials.gov iden-
tiﬁer: NCT00146120] and AMLSG 07-04 [ClinicalTrials.gov identiﬁer:
NCT00151242]). Pediatric AML samples for patient-derived xenografts
were collected from patients enrolled in AML Berlin-Frankfurt-Mu¨nster
treatment protocols for children and adolescents. Written informed
consent was obtained from all patients or custodians in accordance with
the Declaration of Helsinki and local laws and regulations, and the study
was approved by the institutional review board of each participating center.
Mice and Bone Marrow Transplantations
All animal experiments were performed according to protocols
approved by the state government of each institution. Animals were
maintained under speciﬁc pathogen-free conditions. NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (CD45.1), B6.SJL-Ptprca Pepcb/BoyJ (CD45.1), or C57BL/6
mice (CD45.2) were purchased from Charles River Laboratories (Wil-
mington, MA) or bred and maintained at the Animal Facility of Ulm
University orMFDDiagnostics (Wendelsheim, Germany). Transplantation
experiments including lentiviral/retroviral transduction were performed as
previously reported24,25 and as described in the Data Supplement.
RESULTS
miR-193b-3p Expression Was Downregulated in AML
To investigate miR-193b in AML, we proﬁled the expression of
the miRNA in pediatric patients with de novo AML (n = 161)5 via
quantitative real-time polymerase chain reaction. Patient charac-
teristics are summarized in the Data Supplement.
The dominant strand miR-193b-3p (Data Supplement) was
expressed at low levels in the majority of the AML subgroups
compared with total bone marrow from healthy donors (Fig 1A).
Cytogenetically normal (CN-AML), MLL-rearranged (MLL-r),
and t(7;12) cases showed the lowest miR-193b-3p expression
(0.51-, 0.28-, and 0.08-fold change compared with normal bone
marrow, respectively). In contrast, signiﬁcant upregulation of miR-
193b-3p was observed in patients carrying a t(15;17) translocation
(26-fold change compared with normal bone marrow; Fig 1A).
We additionally compared our data with the LAML miRNA-
Seq data set of The Cancer Genome Atlas (TCGA) Research
Network (n = 187).26 In the TCGA data set, miR-193b-3p was
downregulated within the CN-AML group, especially in cases with
FLT3 mutations (0.18-fold change compared with all AML cases;
Fig 1B). In line with the pediatric cohort, miR-193b expression was
signiﬁcantly higher in the t(15;17) group (6.5-fold change com-
pared with all AML cases; Fig 1B).
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Fig 1. Patients with AML express low levels
of miR-193b. (A) Expression of miR-193b-3p in
cytogenetically deﬁned pediatric AML sam-
ples as a percentage of the housekeeping
genes RNU24/48 measured by quantitative
real-time polymerase chain reaction (Taqman;
Thermo Fisher Scientiﬁc, Waltham, MA). (B)
Normalized read counts per million of miR-
193b-3p in The Cancer Genome Atlas cohort of
adult AML samples as determined by micro-
RNA sequencing.26 The gray line indicates the
mean. Pairwise comparisons were performed
using Mann-Whitney U test. AML, acute
myeloid leukemia; CN, cytogenically normal;
FLT3+, FLT3 mutation; N/F+, NPM1 mutation
and FLT3 mutation; NBM, normal bone mar-
row from healthy donors; NPM1+, NPM1
mutation; ns, not signiﬁcant.
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miR-193b Acted as a Tumor Suppressor in Hoxa9/
Meis1-Induced Leukemia In Vivo
The downregulation of miR-193b-3p in various AML sub-
types, particularly in the major pediatric (MLL-r) and adult
(CN-AML) subtypes, led us to hypothesize that suppression of
miR-193b is oncogenic. To test this, we used Hoxa9/Meis127 to
transform lineage-negative (Lin2) CD45.2+ bone marrow cells from
miR-193b2/2 and miR-193b+/+ mice, enabling us to study leuke-
mogenesis in vitro and in vivo (Fig 2A). HOXA9 and MEIS1 are
highly upregulated in MLL-r AML as well as CN-AML, and are
crucial downstream effectors of the MLL fusion protein during
leukemia induction.28,29 Because the MLL-r and CN-AML
subgroups showed the lowest miR-193b-3p expression, the
Hoxa9/Meis1 model was most relevant for investigating the
potential tumor suppressive role of this miRNA. During in vitro
culture, we only observed a marginal increase of cells in S phase
in the absence of miR-193b (Fig 2B). In contrast, upon trans-
plantation into CD45.1 recipients, the leukemic engraftment and
expansion of Hoxa9/Meis1–transduced miR-193b2/2 cells were
enhanced (65% v 47% engraftment after 21 days; P = .0001;
Fig 2C). Consequently, thesemice exhibited a signiﬁcantly shortened
median survival (41 v 50 days; Plog-rank = .0006; Fig 2D).
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Fig 2. miR-193b modulates Hoxa9/
Meis1–induced leukemia in vivo. (A) Ex-
perimental setup of Hoxa9/Meis1–induced
leukemia in the CD45.1/CD45.2 mouse
transplantation model using Lin2 BM cells
of miR-193b2/2 or miR-193b+/+ donors.
(B) Cell-cycle analysis of Hoxa9/Meis1–
transduced Lin2 BM cells of miR-193b2/2
or miR-193b+/+ donors grown in vitro. Data
are presented as mean 6 standard de-
viation of three independent experiments
(Mann-WhitneyUtest;*P, .05). (C)Percentage
of donor cell engraftment (CD45.2+GFP+)
21 days after transplantation measured in the
peripheral blood of recipient mice (n = 7 to 9
per group; Mann-Whitney U test; *P , .05).
(D) Kaplan-Meier survival analysis of recipient
mice (n = 7 to 9 per group; log-rank test).
All mice died of leukemia. (E) Experimental
setup of ectopic miR-193b expression in
Hoxa9/Meis1–induced leukemia in Lin2 BM
cells. (F) Cell-cycle analysis of miR-193b– or
miR-ctrl–transduced cells grown in vitro (n = 2;
Mann-WhitneyU test; **P, .01). (G) Fraction
of BFP+ miR-193b–transduced cells normal-
ized to themiR-ctrl–transduced control (n = 2).
Data are presented as mean 6 standard
deviation (two-way analysis of variance;
*P , .05; **P , .01). (H) Percentage of
donor cell engraftment (CD45.1+ [left] or
GFP+ [right]) 14 days after transplantation
measured in the peripheral blood of re-
cipient mice transplanted with Hoxa9/Meis1/
miR-ctrl or Hoxa9/Meis1/miR-193b (n = 5;
Mann-Whitney U test; **P, .01). BM, bone
marrow; BMMNC, bone marrow mono-
nuclear cell; BrdU, bromodeoxyuridine; ctrl,
control; PB, peripheral blood.
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After showing that the absence of miR-193b accelerates
progression of leukemia and induces a more aggressive disease in
aHoxa9/Meis1murine model of AML, we speculated that inversely,
ectopic expression of miR-193b would impair leukemic growth in
the same model (Fig 2E). Lentiviral overexpression of miR-193b
decreased the proliferation rate and cell-cycle progression in vitro
(Figs 2F and 2G) and delayed the engraftment of Hoxa9/Meis1–
transduced, wild-type bone marrow cells in vivo (2% v 33% en-
graftment after 14 days; P , .001; Fig 2H). Similarly, restoring
miR-193b expression in miR-193b2/2 bone marrow cells impaired
leukemic engraftment (Data Supplement). Together, the results of
these in vivo studies suggest that miR-193b exerts a strong en-
dogenous tumor suppressor function in the hematopoietic system.
Ectopic Expression of miR-193b Impaired Growth of
Human AML Cells
Patients with MLL-r leukemia constitute approximately 35%
of pediatric AML cases and exhibit major heterogeneity due to 70
different potential fusion partners of theMLL gene.30 To investigate
the tumor suppressive function of miR-193b in human disease, we
lentivirally expressedmiR-193b (Data Supplement) in three cell lines
harboring two different MLL translocations: ML-2 (MLL-AF6),
NOMO-1, and MOLM-13 (MLL-AF9). Growth competition assays
showed a growth disadvantage for all miR-193b–transduced MLL-r
cell lines (Fig 3A). Moreover, miR-193b impaired the colony-
forming capacity and enhanced monocytic differentiation induced
by calcitriol of ML-2 and NOMO-1 cells (Figs 3B and 3C). The
effects of miR-193b were accompanied by a reduction of cells in
S phase, as well as an increase of apoptotic and dead cells (Fig 3D;
Data Supplement), highlighting the tumor suppressor potential of
miR-193b in MLL-r AML via reduction of leukemic growth, in-
duction of apoptosis, and promotion of monocytic differentiation.
We further evaluated whether the observed tumor suppressor
effects of miR-193b are restricted to MLL-r leukemia. Ectopic
expression of miR-193b in CMK (complex karyotype), HT93
(t[15;17]), and SKNO-1 (t[8;21]) cells signiﬁcantly reduced cell
growth and colony-forming capacity (Figs 3E and 3F), induced
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apoptosis (Data Supplement), and decreased the fraction of cells in
S phase (Fig 3G). These data provide additional evidence that miR-
193b plays important tumor suppressor roles within a broader
subset of AML subtypes through interference with cell-cycle
progression, differentiation, and viability.
miR-193b Exerted Tumor Suppressive Properties in
Primary Human AML Samples
Next, we extended our ﬁndings to primary human CN-AML
samples (n = 5) with wild-type NPM1 and, except for one sample,
wild-type FLT3. Lentivirally expressed miR-193b abrogated colony
formation in all but one patient sample (Fig 3H), which was
NPM1/FLT3 wild-type and did not exhibit any known unique
characteristics.
To test a potential therapeutic value of miR-193b restoration,
miR-193b (GFP+)– or miR-control (dTomato+)–transduced, MLL-r
patient-derived AML xenografts of two patients were mixed in a 1:1
ratio and competitively transplanted into sublethally irradiated
quaternary recipients (Fig 3I). The miR-193b–transduced AML
blasts were diminished over time and almost absent in the bone
marrow, spleen, and liver of leukemic mice (Fig 3I).
Together, these data from primary human AML blasts and
patient-derived xenografts suggest that restoring miR-193b can
halt leukemic growth in vitro and in vivo, implicating a future
therapeutic potential.
miR-193b Targeted Key Regulators of the MAPK
Pathway
To understand the molecular mechanism of the tumor sup-
pressor phenotype of miR-193b, we screened for potential target
genes. Because of the drastic effects of miR-193b on AML cells, we
reasoned that the effect of miR-193b was unlikely to be caused by
a single target, such as KIT,31,32 but rather would be mediated
through multiple targets leading to a complete block of at least one
essential signaling cascade. Therefore, we mapped predicted miR-
193 targets (TargetScan33) to KEGG pathways. Interestingly, the
MAPK pathway was enriched for miR-193 targets: KIT, KRAS, and
SOS2, as well as the downstream cell-cycle effector CCND1 (Fig
4A). We demonstrated that ectopic expression of miR-193b
downregulated all four genes at the mRNA and protein levels
(Figs 4B and 4C). Luciferase reporter assays conﬁrmed direct
targeting of the complementary seed region of miR-193b to the 39
untranslated regions of all four mRNAs (Fig 4D). To test whether
downregulation of CCND1, KIT, KRAS, or SOS2 could recapitulate
the phenotype caused by miR-193b expression, we performed
in vitro short hairpin RNA (shRNA)-mediated knockdown ex-
periments using two validated shRNAs per gene (Data Supple-
ment). We observed a decrease in the proliferation of SKNO-1 and
CMK cells lentivirally transduced with each of these shRNA
constructs compared with the nonsilencing shRNA control, as well
as a reduction of cells in S phase (Fig 4E; Data Supplement).
Next, we assessed whether the downregulation of miR-193b,
as seen in CN and MLL-r AML cases, increased MAPK signaling.
To do so, we measured the expression of KIT and phosphorylation
of ERK and STAT5 (other downstream signal transducers of KIT
and indirect targets of miR-193b23) in Hoxa9/Meis1–transduced
miR-193b2/2 or miR-193b+/+ bone marrow cells. KIT levels were
elevated and both STAT5 and ERK exhibited increased phos-
phorylation in the absence of miR-193b, demonstrating increased
activation (Fig 4F).
Last, we tested whether restoring KITexpression could render
leukemic cells resistant to the tumor suppressive function of miR-
193b. We could demonstrate that ectopic expression of a mouse Kit
or human KIT cDNA, respectively, without miR-193b target sites,
was not able to overcome the growth disadvantage, cell-cycle
inhibition, and apoptosis induced by ectopic miR-193b in
Hoxa9/Meis1–transformed murine leukemic cells or in the human
cell lines SKNO-1 and CMK (Figs 4G and 4H; Data Supplement).
Our data imply that miR-193b acts as tumor suppressor by
targeting theMAPK signal cascade at multiple steps, thereby tightly
controlling cell proliferation and cell-cycle progression (Fig 4A),
and that restoring only one target is insufﬁcient to abrogate these
antileukemic effects of miR-193b.
miR-193b as a Prognostic Factor in AML
miR-193b exerts tumor suppressive functions across multiple
AML subgroups and loss of miR-193b shortens survival in the
Hoxa9/Meis1-induced leukemia mouse model. Therefore, we in-
vestigated the prognostic effect of miR-193b in AML. We stratiﬁed
a cohort of 161 pediatric patients5 on the basis of miR-193b-3p
expression (Fig 1A; Data Supplement). The optimal cutoff was
determined by maximally selected rank statistics adjusted for
multiple testing34 (Data Supplement). Kaplan-Meier analysis
demonstrated that low miR-193b-3p expression was signiﬁcantly
associated with a lower overall survival (OS; 71% v 45% after
5 years; Plog-rank =.0016; Fig 5A) and event-free survival (EFS; 49%
v 31% after 5 years; Plog-rank =.018; Fig 5B). Expression of the
passenger strand (miR-193b-5p) did not predict survival (Data
Supplement).
In the multivariate analysis, including white blood cell count,
age, and risk group stratiﬁcation as established prognostic pa-
rameters,35 low miR-193b-3p expression was validated as an in-
dependent factor for poor prognosis (Table 1; Data Supplement).
Furthermore, the prognostic value of miR-193b-3p was retained
when excluding the patients with t(15;17) (OS Plog-rank = .002; EFS
Plog-rank = .025), who have a high expression of miR-193b-3p and
are characterized by an excellent survival even without chemo-
therapy36 (Data Supplement). Most importantly, lowmiR-193b-3p
expression identiﬁed patients with a very poor prognosis within the
European LeukemiaNet intermediate/adverse-risk group (Figs 5C
and 5D; Data Supplement). Moreover, miR-193b-3p expression
improved the prognostic value of the recently reported LSC17
signature.37 Within the LSC17 high-risk patients, miR-193b-3p
expression further stratiﬁed those with a very high risk and an even
worse OS (Plog-rank = .003) and EFS (Plog-rank = .005; Figs 5E and
5F; Data Supplement).
Of note, in the TCGA adult AML data set, low miR-193b-3p
expression was also associated with a signiﬁcantly worse OS
(Plog-rank = .014) and EFS (Plog-rank = .0005; Data Supplement).
The results of these analyses not only identify miR-193b-3p
expression as a prognostic factor, but also imply that delivery of
miR-193 mimetics may be a promising therapeutic approach for
pediatric and adult patients with AML. Identiﬁcation of patients at
very high risk, on the basis of their low miR-193b-3p expression,
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Fig 4. miR-193b targets the MAPK (KIT-RAS-RAF-MEK-ERK) pathway. (A) The oncogenic MAPK (KIT-RAS-RAF-MEK-ERK) pathway is enriched for miR-193b targets
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may help to better allocate patients to hematopoietic stem-cell
transplantation.
DISCUSSION
Here, we introduce miR-193b as an endogenous tumor suppressor
of the hematopoietic system and independent prognostic marker in
AML. We provide compelling mechanistic evidence that miR-193b
orchestrates the pivotal MAPK signaling pathway to control viability
and proliferation, which is often constitutively activated in AML and,
therefore, opens opportunities for antileukemic strategies.
Knockout of miR-193b in the Hoxa9/Meis1 in vivo model
caused a more aggressive form of leukemia, resulting in a signiﬁ-
cantly decreased survival of the recipient mice. Thus, in addition to
its known function as a gate keeper in normal hematopoietic stem
cells that regulates stem-cell function by controlling proprolifer-
ative pathways in a STAT5-dependent negative feedback loop,23 we
describe here the critical function of miR-193b as a potent sup-
pressor of leukemic growth. In fact, miR-193b and its family
membermiR-193a have been suggested to act as tumor suppressors
in certain types of leukemia, such as T-lymphoblastic leukemia or
AML with t(8;21),31,32,38,39 as well as in several solid tumors,
including lung and ovarian cancers.40-44 Our study sheds light on
the essential mechanism beyond the former observations and
establishes a global role of miR-193b as an endogenous tumor
suppressor in the hematopoietic system.
In a Hoxa9/Meis1–driven AML model, the absence of miR-
193b corresponded with upregulation of STAT5, and RAS/RAF/
ERK signaling, mediated by the lack of miR-193b–regulated ﬁne
tuning of at least four key target genes: KIT, KRAS, SOS2, and
CCND1. All four identiﬁed target genes are components of the
MAPK pathway (Fig 4A), which interferes with other pathways.
CCND1 provides a link between the MAPK pathway and cell-cycle
progression.17-19 The RAS-RAF-MEK-ERK cascade regulates the
activity of CCND1 and the formation of the CCND1/CDK6
complex, thereby controlling G1/S transition.17-19
Activating mutations in the MAPK pathway represent a fre-
quent event in the progression of leukemia and other
malignancies.15,16 KITmutations appear in approximately 12% to
25% of cases with inv(16)(p13q22) and t(8;21) AML,45 in which
the tumor suppressive functions of miR-193a through targeting
KIT and CCND1 were ﬁrst described in AML.39 Targeting the
MAPK axis remains a long-sought goal in cancer therapies, al-
though development of such therapies has been hampered by
several obstacles.46 Most notably, the oncogenic RAS protein was
considered untargetable with drugs.46 In addition, therapeutic
interference with activated transcription factors, such as STATs, is
inherently difﬁcult. Although efﬁcient inhibitors of RAF, MEK,
ERK, and tyrosine kinases have been developed,22,47 they have
failed to provide a survival beneﬁt in clinical trials.10 Currently,
many cancer therapies that target a single oncogene merely in-
duce a modest therapeutic response; moreover, they increase the
possibility of acquiring mutations that cause therapy resistance.
Thus, the ability to repress many oncogenes at once and across
different oncogenic pathways provides a strong rationale for
developing miRNA-based cancer therapeutics.
The strategy of inhibiting multiple targets in one pathway by
using a single molecule is still in its infancy. Here, we present miR-
193b to target multiple important hubs of leukemia cell signaling
simultaneously, including transcription factors. We were able to
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the 39 untranslated region ofCCND1, KIT, KRAS, and SOS2 in HEK293 T cells transfectedwithmiR-193b ormiR-ctrl (n = 3). (E) shRNAmediated knockdown of the predicted
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identify four direct targets of miR-193b within the MAPK pathway.
In this case, even if a mutation were to arise in the mRNA–miRNA
binding region of one of the four target genes, miR-193bwould still
be able to target three other genes of this pathway. This would
impede the fast development of resistancemechanisms. In fact, our
data show that miR-193b–resistant KITwas not able to overcome
the tumor suppressive effect of miR-193b. Only in AML cases with
t(15;17) was the miR-193b-3p expression high and an miR-
193b–based treatment must be carefully evaluated, given the rel-
evant role of theMAPK pathway for all-trans retinoic acid–induced
differentiation.48
Similar approaches using miRNA mimetic agents are cur-
rently in clinical trials.11-13 miR-16 mimics are undergoing phase I
clinical trials in patients with malignant pleural mesothelioma or
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non–small-cell lung cancer for whom standard therapy was in-
effective. The miR-16 mimics are delivered intravenously using
EnGeneIC Dream Vector packaging (Sydney, New South
Wales, Australia) and are conjugated with an epidermal growth
factor receptor-targeting antibody12—a strategy that could be
applied to miR-193b.14 At this stage, miR-193b-3p expression
can be used to infer treatment recommendations for chil-
dren with AML. Patients in the European LeukemiaNet
intermediate/adverse-risk group or with a high LSC17 score,
who have low miR-193b-3p expression, have a poor prognosis
and may be allocated to hematopoietic stem-cell trans-
plantation. Still, the retrospective nature of our analysis is
a potential limitation.
In conclusion, our work identiﬁes miR-193b as a global
antileukemic miRNA in AML and as a suppressor of essential
signaling pathways, paving the road for a clinical application. MiR-
193b further stands out as potential tool for AML prognosis,
promising higher chances for its entrance into therapeutics.
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